Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers-Reference-Cited by-同舟云学术

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

Published:2014-06-21 Issue:2 Volume:146 Page:421-427
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Gronwald Jacek, ,Robidoux Andre,Kim-Sing Charmaine,Tung Nadine,Lynch Henry T.,Foulkes William D.,Manoukian Siranoush,Ainsworth Peter,Neuhausen Susan L.,Demsky Rochelle,Eisen Andrea,Singer Christian F.,Saal Howard,Senter Leigha,Eng Charis,Weitzel Jeffrey,Moller Pal,Gilchrist Dawna M.,Olopade Olufunmilayo,Ginsburg Ophira,Sun Ping,Huzarski Tomasz,Lubinski Jan,Narod Steven A.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-014-3026-3.pdf

Reference24 articles.

1. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689

2. Metcalfe K, Gershman S, Lynch HT et al (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104:1384–1392

3. Narod SA, Brunet JS, Ghadirian P, Hereditary Breast Cancer Clinical Study Group et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case–control study. Lancet 356:1876–1881

4. Gronwald J, Tung N, Foulkes WD, Hereditary Breast Cancer Clinical Study Group et al (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118:2281–2284

5. Phillips K, Milne RL, Rookus MA et al (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31:3091–3099

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stem Cell Division and Its Critical Role in Mammary Gland Development and Tumorigenesis: Current Progress and Remaining Challenges;Stem Cells and Development;2024-09-01

2. Choices for cancer prevention for women with a BRCA1 mutation? a personal view;Hereditary Cancer in Clinical Practice;2023-11-29

3. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation;Breast Cancer Research and Treatment;2023-07-11

4. Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study;Swiss Medical Weekly;2023-03-30

5. Familial Breast Cancer;Holistic Approach to Breast Disease;2023